Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of CaN-001 in rheumatoid arthritis
MOH_2021-10-05_010288Phase 2Not yet recruiting
- Sponsor
- Cannassure Therapeutics Ltd
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CAN-001 in rheumatoid arthritis (RA), sponsored by Cannassure Therapeutics Ltd. Primary endpoints: Safety assessments and Change in Rheumatoid Arthritis Severity Scale response. Status: not yet recruiting.
02
Drugs
CAN-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2021-10-05_010288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-05_010288.